
US Accepts Biologics License Application for Datopotamab Deruxtecan in Advanced HR-Positive, HER2-Negative Breast Cancer Post-Prior Treatment
AstraZeneca and Daiichi Sankyo’s Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been officially accepted in the United States. This application targets the treatment of adult patients grappling with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative (IHC 0, IHC…











